Background. A recent clinical trial showed harmful renal effects with the combined use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) in people with diabetes or vascular disease. We examined the benefits and risks of these agents in people with albuminuria and one or more cardiovascular risk factors.
Methods. MEDLINE, EMBASE and Renal Health Library were searched for trials comparing ACEI, ARB or their combination with placebo or with one another in people with albuminuria and one or more cardiovascular risk factor. Results. Eighty-five trials (21 708 patients) were included. There was no significant reduction in the risk of all-cause mortality or fatal cardiac-cerebrovascular outcomes with ACEI versus placebo, ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI 1 ARB versus monotherapy. There was a significant reduction in the risk of nonfatal cardiovascular events with ACEI versus placebo but not with ARB versus placebo, ACEI versus ARB or with combined therapy with ACEI 1 ARB versus monotherapy. Development of end-stage kidney disease and progression of microalbuminuria to macroalbuminuria were reduced significantly with ACEI versus placebo and ARB versus placebo but not with combined therapy with ACEI 1 ARB versus monotherapy. Conclusions. ACEI and ARB exert independent renal and nonfatal cardiovascular benefits while their effects on mortality and fatal cardiovascular disease are uncertain. There is a lack of evidence to support the use of combination therapy. A comparative clinical trial with ACE, ARB and its combination in people with albuminuria and a cardiovascular risk factor is warranted.
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Background
Micro-and macroalbuminuria are found in~9.5% of the adult population in the USA and 6-30% of people with hypertension and diabetes [1] [2] [3] [4] . Increased urinary albumin excretion rate has been recognized as an independent risk factor for cardiovascular and chronic kidney disease [5] . The concomitant presence of albuminuria, hypertension and diabetes confer a 2-to 8-fold increase in the risk of cardiovascular morbidity and mortality [6] [7] [8] [9] . Similarly, the concomitant presence of microalbuminuria and other cardiovascular risk factors such as smoking, obesity and dyslipidemia (components of the metabolic syndrome) significantly increase the risk of cardiovascular disease [10, 11] .
Several guidelines suggest that angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) are equivalent and are preferred agents in patients with microalbuminuria due to significant reductions in all-cause mortality, cardiovascular events and progression of chronic kidney disease [12] [13] [14] [15] . Such recommendations are based on existing randomized trials and meta-analyses [16] . Combined therapy with ACEI and ARB has also become more broadly adopted based primarily on biological plausibility that more intense blockade of the RAAS using multiple approaches are likely to be more effective, but there are relatively few empirical data from randomized trials [17] . The recently published ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) has raised a vigorous debate in the scientific community [18] . Contrary to prevailing expectations, this study found no incremental advantage for cardiovascular morbidity and mortality with combined therapy of high doses of telmisartan and ramipril compared to each of the two monotherapies in a high cardiac risk population (previous cardiovascular events or diabetes with target organ damage) [19] . Combined therapy was also associated with a worsening of some kidney outcomes. However, a question that is often raised is whether the effects of combined therapy would be beneficial in those with preexisting renal damage.
In this systematic review, we evaluate the benefits and risks of ACEI and ARB for the prevention of progression of kidney disease, cardiovascular events and all-cause mortality in patients with albuminuria and one or more cardiovascular risk factors. We also explore the cardiorenal effects and adverse effects of the combined therapy with ACEI plus ARB compared to each monotherapy in people with albuminuria and at least one cardiovascular risk factor.
Methods
This review was conducted and reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) criteria [20] .
Data sources and search strategies
We searched MEDLINE (1950 to April 2009), EMBASE (1980 to April 2009) and CENTRAL (2009-latest issue) for randomized controlled trials (RCTs) of Renin-Angiotensin System (RAS) Inhibitors in micro-and macroalbuminuric patients with one or more cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking, visceral obesity or a family history of cardiovascular disease). We used optimally sensitive search strategies developed by the Cochrane Collaboration (Appendix 1). The search words 'angiotensin-converting enzyme inhibitor, angiotensin receptor blocker' and individual drug names in the 'ACEI' and 'ARB' class were used. The risk factors were identified by text words and major MeSH headings as applicable. Two authors (A.M. and S.D.N.) independently reviewed all titles and abstracts of RCTs and, where necessary, the full text, selecting the ones which met the inclusion criteria. Reference lists of included studies were also screened in search for relevant eligible publications. Reviewers also sought information about unpublished or additional RCTs from the Internet and approached experts in the field of inquiry for additional studies.
Inclusion criteria
We included any placebo-controlled RCTs or head-to-head trials of ACEI and ARB. We also included comparative trials of ACEI 1 ARB versus monotherapy. Trials were eligible if the intervention was administered for at least 6 months and if they enrolled patients with microalbuminuria or macroalbuminuria and at least one other cardiovascular risk factor. We also included data from trials that had a proportion of patients who had at least one cardiovascular risk factor and microalbuminuria. Any definition of microalbuminuria and macroalbuminuria provided by trialists was considered, reported as either urinary albumin excretion rate (expressed as milligram per 24 h or lg/min) or urinary albumin:creatinine ratio (expressed as milligram per gram creatinine or milligram per millimole creatinine). Studies were included in this systematic review independent of outcomes they reported. However, only studies reporting major clinical events such as mortality or cardiovascular events were included in our meta-analysis.
Data extraction and risk of bias
Data extraction was carried out independently by the same two independent reviewers (A.M. and S.D.N.) using standard data extraction forms. We extracted data on the characteristics of the participants, interventions, comparisons and hard benefit/harm patient-level outcomes [including all-cause mortality, fatal and nonfatal myocardial infarction, fatal and nonfatal stroke, sudden death, hospitalizations for any cardiovascular cause, angina, transient ischemic attack, congestive heart failure, cardiac revascularization, end-stage kidney disease (ESKD), doubling of serum creatinine concentration, progression of microalbuminuria to macroalbuminuria, regression from microalbuminuria to normoalbuminuria, regression from macroalbuminuria to microalbuminuria or normoalbuminuria, cough, peripheral edema, angioneurotic edema, hyperkalemia, nausea, headache, dryness of mouth and hypotension). Data on surrogate end points (including markers of kidney or cardiovascular disease, like proteinuria, albuminuria, serum creatinine, glomerular filtration rate and others) were not collected.
Any missing or unclear information in the reports of RCTs was requested from trial authors by written correspondence at least twice. We used standard criteria to assess the quality of the methods of the included RCTs; explored domains were allocation concealment, blinding, use of intention-to-treat (ITT) analysis and the proportion of patients lost to follow-up in the trials. Concealment of allocation was considered adequate if the randomized method described in the text did not allow the investigators and the participants to know or influence the intervention group before the randomized allocation. Information on blinding of investigators, participants, outcome assessors and data analysis was collected. The analysis was considered as ITT if all patients included were analyzed in the same group to which they were originally allocated, regardless of the treatment they received.
We assessed 'lost to follow-up' as the proportion of patients who discontinued follow-up without any known reason and whose data could not be identified in the trial analysis. Disagreements among reviewers were resolved in consultation with an arbitrator (Giovanni F. M. Strippoli). Studies were considered without language restriction; the full text of non-English language articles was translated only in cases where it was evident from the abstract and visual analysis of tables and figures that they may contribute hard outcome data to the analysis.
Statistical analysis
We summarized treatment effects as relative risks (RR) with 95% confidence intervals (CIs) using a random-effects model but the fixed effects model was also used to check reliability of data and susceptibility to outliers. Heterogeneity of treatment effects between studies was analyzed formally using the Cochran Q and the I 2 statistics [21] and by subgroup analysis to identify potential effect modifiers among characteristics of the patients (hypertension, diabetes, smoking, dyslipidemia, visceral obesity, cardiovascular family history and stage of albuminuria), the drug (type of agent and dose) and study methods (number of trial participants, allocation concealment, blinding, ITT analysis, loss to follow-up and duration of follow-up). Between group interactions were tested with a Mantel-Haenszel test. All analyses were performed with SAS Version 9.1 (SAS Institute, Cary, NC) and RevMan 4.2.10.
Results
Of 2820 articles identified by the searches, 2463 were excluded after review of the titles and abstracts (Figure 1 ). The major reasons for exclusion are provided in the flowchart. After assessing the full text of 357 studies, we included 85 eligible RCTs (from 86 publications) which enrolled 21 708 patients [19, 22- 
Study characteristics
Of the 85 RCTs, 52 (11 125 patients) compared ACEI with placebo, 9 (4550 patients) compared ARB with placebo, 12 (4969 patients) compared combination therapy with each monotherapy and 12 (1064 patients) did a head-to-head comparison between ACEI and ARB ( Table 1) .
All RCTs had a parallel study design, except for two that were crossover trials but did not contribute to the analysis since only surrogate outcomes were reported. There were four non-English language studies included in the review (one Serbian, one German, one Polish and one Chinese); we did not fully translate these studies as only surrogate data were reported. Requests of additional information for 21 studies were successful for nine RCTs [18, 19, 23, 24-30, 44, 46, 48, 74, 78, 89, 92] , and data were included in our analyses. This supplemental information also includes data on the micro-and macroalbuminuric subsets of two recently published large trials, the ONTARGET and the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (Transcend) studies [19, 78] . Five studies mentioned inclusion of micro-and macroalbuminuric patients but did not report specifically on these subgroups nor provide data upon request [41, 83, 88, 106, 107] . Three studies did not specify the number of micro-and macroalbuminuric patients enrolled [41, 88, 106] .
Study quality
The quality of the included studies was evaluated in 81 
Study results
All analyses were dominated by few trials [19, 37, 44, 76] .
All-cause mortality
There was no significant reduction in the risk of all-cause mortality with ACEI compared to placebo or no treatment (14 RCTs, 8980 patients, RR 0.93, 95% CI 0.73-1.18 ( Figure 2 ). In four trials (3888 patients) comparing ARB versus placebo or no treatment, there was no statistically significant reduction in the risk of all-cause mortality with ARB (RR 1.01, 95% CI 0. 88-1.16) . No statistically significant reduction in the risk of all-cause mortality was also found in the three head-to-head trials (3019 patients) of ACEI versus ARB (RR 1.08, 95% CI 0.94-1.24). There was no statistically significant reduction in the risk of allcause mortality with combined therapy with ACEI 1 ARB when compared to each monotherapy (ACEI 1 ARB versus ACEI: one RCT, 2652 patients, RR 0.91, 95% CI 0.79-1.05 and ACEI 1 ARB versus ARB: 1 RCT, 2700 patients, RR 0.99, 95% CI 0.86-1.14).
Fatal and nonfatal cardiovascular outcomes
Fatal cardiovascular events. There was no significant reduction in the risk of fatal cardiocerebrovascular events with ACEI compared to placebo or no treatment (six RCTs, 7873 patients, RR 0.94, 95% CI 0.65-1.37) ( Table 2 ).
In two trials (1785 patients) comparing ARB versus placebo or no treatment, there was no significant reduction in the risk of fatal cardiocerebrovascular events (RR 1.10, 95% CI 0.81-1.50).
No statistically significant reduction in the number of fatal cardiovascular events was found in the two head-to-head trials (2930 patients) of ACEI versus ARB (RR 0.80, 95% CI 0.61-1.04) with no heterogeneity between studies. There was no significant reduction in the risk of all fatal cardiocerebrovascular events with combined therapy with ACEI 1 ARB when compared to each monotherapy (ACEI 1 ARB versus ACEI: 1 RCT, 2652 patients, RR 0.95, 95% CI 0.71-1.27 and ACEI 1 ARB versus ARB: one RCT, 2700 patients, RR 0.77, 95% CI 0.58-1.01).
Nonfatal cardiovascular events. There was a significant reduction in the risk of nonfatal cardiovascular events with ACEI compared to placebo or no treatment (nine RCTs, 8231 patients, RR 0.88, 95% CI 0.82-0.94).
In four trials (3888 patients) comparing ARB versus placebo or no treatment, there was a significant reduction in the risk of nonfatal cardiocerebrovascular events (RR 0.77, 95% CI 0.61-0.98). There was an evidence of significant heterogeneity in this analysis (Q ¼ 11.5, P ¼ 0.009, I
2 ¼ 73.9%). No significant difference in the risk of nonfatal cardiovascular events was found in the three head-to-head RCTs (3290 patients) of ACEI versus ARB (RR 1.00, 95% CI 0.93-1.07) with no heterogeneity between studies. There was no significant reduction in the risk of all nonfatal cardiocerebrovascular events with combined therapy with ACEI 1 ARB when compared to each monotherapy (ACEI 1 ARB versus ACEI: one RCT, 2652 patients, RR 1.03, 95% CI 0.96-1.10 and ACEI 1 ARB versus ARB: one RCT, 2700 patients, RR 1.03, 95% CI 0.96-1.11).
Kidney outcomes
There was a significant reduction in the risk of all kidney outcomes with ACEI compared to placebo or no treatment (ESKD: 9 RCTs, 7988 patients, RR 0.67, 95% CI 0.54-0.84; doubling of serum creatinine: 9 RCTs, 8460 patients, RR 0.62, 95% CI 0.46-0.84 and progression from micro-to macroalbuminuria: 18 RCTs, 2888 patients, RR 0.49, 95% CI 0.36-0.65) ( Figure 3 , Table 2 ). There was a significant increase in the likelihood of regression from micro-to normoalbuminuria (15 RCTs, 1860 patients, RR 2.99, 95% CI 1.82-4.91).
There also was a significant reduction in the risk of all kidney outcomes with ARB compared to placebo (ESKD: three RCTs, 3298 patients, RR 0.78, 95% CI 0.66-0.90; doubling of serum creatinine: three RCTs, 3298 patients, RR 0.78, 95% CI 0.68-0.90 and progression from micro-to macroalbuminuria: five RCTs, 1907 patients, 0.45, 0.37-0.54). Similar to the effects noted for ACEI, there was a significant increase in the risk of regression from micro-to normoalbuminuria with ARB (four RCTs, 1211 patients, RR 2.83, 95% CI 1.14-7.07).
Two trials (3019 patients) that compared ACEI with ARB reported the outcome of ESKD and found no 
Adverse effects
Adverse effects were reported only in a few trials. Table 3 shows summary estimates of the effects of ACEI, ARB and their combination on cough, hyperkalemia, hypotension, headache, angioneurotic edema, peripheral edema and nausea. A significant increase in the risk of cough was found with the ACEI when compared to ARB, but no other significant differences (including the incidence of hyperkalemia) were noted among these agents (Table 3) .
Subgroup analysis and metaregression
Although there was no significant heterogeneity in most of our analyses, subgroup analyses and metaregression were performed as stated 'a priori' in the scientific protocol to specify the role of potentially significant effect modifiers. These analyses were possible only in trials comparing ACEI with placebo given the small number of trials evaluating comparisons of ARB versus placebo, ACEI versus ARB and combined therapy versus each monotherapy that reported relevant outcomes. The results are reported in Table 4 .
Discussion
In patients with albuminuria and at least one other cardiovascular risk factor, both ACEI and ARB reduced the risk of progression of kidney disease compared with placebo. Compared with placebo, ACEI and ARB were associated with significant reductions in the risk of nonfatal cardiovascular events but neither was associated with a clear change in the risk of fatal CV events and all-cause mortality. Head-to-head trials of ACEI versus ARB demonstrated no significant differences of these agents with respect to cardiovascular and kidney protection. Despite biological plausibility and the expectations from the ONTARGET trial, compared with ACEI or ARB monotherapy, combination therapy was not shown to be superior for kidney or cardiovascular end points and was associated with comparable adverse event rates, except for a higher risk of cough compared with ARB therapy alone and a higher risk of hypotension compared with ACEI therapy alone. The relationships between increasing levels of albuminuria and the risks of death and cardiovascular events in diabetic and nondiabetic patients have long been established [4, 76, [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] . Inhibition of the RAS by ACEI and/or ARB engenders a reduction in albuminuria/proteinuria independent of the baseline degree of albuminuria/ proteinuria and underlying disease [117] and has become standard practice for delaying the progression of kidney disease and reducing cardiovascular outcomes both in patients with diabetic nephropathy [12] [13] [14] [15] [16] [120] [121] [122] and in nondiabetic albuminuric patients [123] . The benefits of ACEI and ARB appear to be disproportionate to the degree of blood pressure reduction [74, [124] [125] [126] [127] and proportional to the degree of baseline proteinuria and its reduction following treatment [43, [128] [129] [130] .
Until recently, most of the evidence pertaining to RAS inhibition and cardiovascular and kidney protection was derived from placebo-controlled RCTs of ACEI or ARB with relatively few RCTs evaluating the comparative efficacy of ACEI versus ARB head to head [131, 132] . Our analysis was the first to directly compare the effects of taking ACEI versus ARB on patient-level cardiovascular and kidney outcomes in a large number of albuminuric patients. We found that the two classes of RAS inhibitors were comparable with respect to all cardiovascular and kidney outcomes evaluated. These findings are in keeping with those of a previous meta-analysis, which reported that the magnitudes of reduction in proteinuria following ARB and ACEI therapy are similar [120] .
Although monotherapy with ACEI and ARB resulted in significant improvements in both cardiovascular and kidney end points, these did not translate into a consistent reduction in all-cause mortality. This may represent a type-2 statistical error since none of the studies was designed to primarily evaluate mortality. Nevertheless, the number of deaths was relatively large (up to 1064 in the ACEI versus placebo trials), even though only a proportion of these deaths would be anticipated to be amenable to antiproteinuric therapy via RAS inhibition. Alternatively, the beneficial effects of ACEI and ARB on cardiovascular and kidney outcomes might have been counterbalanced by deleterious effects, such as hyperkalemia. Further, RCTs examining the effects of RAS inhibition on the survival of albuminuric patients with heightened cardiovascular risk are warranted. Given the disparate mortality results with high-and low-dose ACEI in the HOPE and DIABHYCAR studies [37, 44] , such trials should use high doses.
Our analysis was also the first to compare the effects of combined ACEI and ARB therapy versus monotherapy on patient-level outcomes. Previous metaanalyses have reported that combined therapy resulted in greater reductions in blood pressure and proteinuria than treatment with either agent alone [120, 133, 134] . It has been postulated that this augmented clinical effect on surrogate markers may represent more complete inhibition of the RAS since ARB mitigate 'ACEI escape' by blocking angiotensin-II produced by chymases and other non-ACE enzymes [135, 136] . The Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-converting-enzyme inhibitor in Nondiabetic Renal Disease (COOPERATE) trial [137] was the only RCT to demonstrate that combination therapy may reduce a clinically relevant outcome (a composite kidney end point) compared with monotherapy in patients with nondiabetic chronic kidney disease but has been recently retracted [138] [139] [140] . In our analysis, we have not included the COOPERATE study results, although analyses with and without COOPERATE were not significantly different for any outcome.
More recently, the ONTARGET trial [19] compared cardiovascular and kidney protection obtained with ACEI (ramipril 10 mg daily), ARB (telmisartan 80 mg daily) and ACEI plus ARB in 25 620 patients aged !55 years with established atherosclerotic vascular disease or with diabetes with end-organ damage. The study demonstrated that combined therapy was no more efficacious than monotherapy with respect to the primary composite cardiovascular outcome (cardiovascular death, myocardial infarction, stroke or hospitalization from heart failure) and was associated with a worse composite kidney outcome (dialysis, doubling of serum creatinine or death). The latter outcome may have been partly explained by a greater incidence of hyperkalemia and hypotension with combination therapy, leading to a significant increase in the requirement for acute dialysis. Moreover, such highrisk vascular patients may have had a significant proportion of patients with renovascular disease, who are at increased risk of acute kidney injury by more complete RAS inhibition. Importantly, albuminuria was present in only a minority (17.1% but still >4300 people) of participants and may have been an important effect modifier. ONTAR-GET participants without albuminuria were at increased risk of the primary kidney outcome with combination therapy, whereas those with albuminuria were not. Nevertheless, even those with albuminuria did not exhibit cardiovascular or kidney benefit from combination therapy. Previous studies have demonstrated that the benefits of ACEI and ARB are directly proportional to the baseline level of albuminuria [43, 128] . Indeed, patients with normal or minimal albuminuria may derive little kidney benefit and may contain a high proportion of patients with renovascular disease prone to kidney (but not cardiovascular) injury with combination therapy.
The neutral cardiovascular effects of combination therapy may also have been due to the high baseline cardiovascular risk (previous major cardiovascular event or diabetes with end-organ damage) and/or the successful treatment of patients with other cardiovascular risk-modifying drugs, namely statins, aspirin and antihypertensive agents, such that little further clinical benefit was possible with dual RAS blockade. It may also be that the incremental benefit of more complete RAS blockade is very small. In our systematic review, only few studies were adequately powered and had sufficient follow-up to examine differences in the risk of all-cause mortality with ACEI/ARB use. Even larger studies had significant methodological differences with respect to the study population, agents used, duration of follow-up etc. Future studies may explore such aspects within longer follow-up duration.
In our meta-analysis on combination therapy, which was strongly dominated by the results of the ONTARGET trial, more complete RAS inhibition resulted in comparable mortality, cardiovascular events and kidney outcomes compared with monotherapy. Adverse event rates were also comparable, except for a higher risk of cough compared with ARB therapy alone and a higher risk of hypotension compared with ACEI therapy alone. These results raise significant concerns about the general validity of reduction in albuminuria/proteinuria as a valid surrogate marker of cardiovascular and kidney protection since the demonstrated superior antiproteinuric effect of combination ACEI/ ARB therapy did not translate into improved patient-level outcomes. The concerns are certainly relevant for people with normal or only moderately elevated urinary albumin excretion.
The rate of renal disease progression in women might be higher than men [141] . Maschio et al. [25] reported a lower risk for progression of renal disease (defined as a doubling of serum creatinine or the need for dialysis) with ACEI in men compared to women [40% (95% CI 2-64) reduction in risk in men versus 35% (95% CI [69] [70] [71] [72] [73] [74] [75] . In subgroup analysis, we found a significant difference in the risk of progression of microalbuminuria to macroalbuminuria in studies that had a smaller proportion of men (less than a Continued median value of 63.5% men) (P for interaction ¼ 0.006). No significant differences in the risk of all-cause mortality, doubling of serum creatinine concentration and development of ESKD was noted based on gender differences (P for interaction > 0.05) ( Table 4) . The strength of this study is that it assessed survival, cardiovascular, kidney and toxicity outcomes by means of a comprehensive systematic review based on a prespecified detailed protocol, with rigid inclusion criteria for RCTs only and a comprehensive search strategy (see Appendix). Data extraction, data analysis and methodological quality assessments were performed by independent investigators. Furthermore, the possibility of publication bias was minimized by including both published and unpublished (e.g. abstracts to meetings) trials. Information about unpublished and ongoing RCTs was sought from authors of the included RCTs, drug companies and experts in the field. According to the Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) approach, a system developed for grading the quality of evidence [142] , our results, obtained from a meta-analysis of RCTs, should be considered as data of high-quality level. However, a metaanalysis is as good as the studies within it and the poor quality of the trials included may affect it.
The major limitation of our review is the small number and suboptimal quality of most of the included studies. Few of the trials included in our metaanalysis had been planned to evaluate the comparative efficacy of RAS inhibitors for reducing the risk of 'hard' end points (survival, cardiovascular events, ESKD, etc.) in albuminuric patients. Instead, most RCTs focused attention on continuous kidney end points only (such as proteinuria, serum creatinine, glomerular filtration rate, etc.) during a short follow-up and accounted for occasional major cardiovascular events and deaths that could not be totally explained by the study and patient characteristics. Some analyses were dominated by one or two large trials, namely the mortality data for ACEI versus placebo dominated by the HOPE and DIA-BHYCAR trials [37, 44] and all analyses of ACEI versus ARB in combination versus monotherapy dominated by ONTARGET [19] .
Another potential limitation of our analysis was that we deliberately excluded collection of surrogate end points. However, recent data in the literature from ONTARGET [19] highlight that even widely evaluated outcome measures, such as proteinuria, remain unvalidated as surrogate end points of kidney disease progression and cardiovascular events. Since the national kidney foundation and the ACC/AHA have specifically recommended that kidney disease should be considered a coronary disease risk equivalent [143] , some studies were included even if not all (100%) albuminuric patients had at least one cardiovascular risk factor (diabetes or hypertension), provided at least a percentage >70% of the entire population had diabetes or hypertension. Our analysis was also unable to retrieve a noteworthy number of studies enrolling smokers or patients with dyslipidemia, visceral obesity and family history of CV disease. We identified no studies specifically conducted in these patients but some studies enrolling a proportion of patients fulfilling these criteria. Studies specifically conducted in these populations may be important to rule out the risk of basing conclusion on extrapolations from larger trials, preliminarily mean to answer the question in different broader populations. We also explored potential publication bias with funnel plots whenever possible and did not find any significant evidence of such bias, although this was only possible in few comparisons given the limited number of trials. [145] .
Implications for research

Implications for practice
Meanwhile, in anticipation of the results of these comparative RCTs, each of the two single monotherapies (ACEI alone or ARB alone) should be prescribed in preference to combined therapy due to the lack of evidence of superiority of these two drugs when administered together. The choice between ACEI and ARB should be based on tolerability as well as economic assessments. 
